Dasotraline: Ph II/III SEP360-221 data

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary reported top-line data from the double-blind, U.S. Phase II/III SEP360-221 trial in about 319 patients ages 18-55 with moderate to severe ...